Fraunhofer Institute for Cell Therapy and Immunology IZI

Fraunhofer IZI steps up research to improve the treatment of infectious cardiovascular diseases

Press release | May 16, 2018

more info

Fighting pathogens with sugar molecules

Press release | May 17, 2018

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career





Press information / 17.5.2018

Fighting pathogens with sugar molecules

Sugar can have many negative effects on the body. Overconsumption can give rise to obesity, high blood pressure and even diabetes. But there is more to sugar than meets the eye. For their next joint project, scientists from the Fraunhofer Institute for Cell Therapy and Immunology IZI and the Max Planck Institute of Colloids and Interfaces (MPIKG) have set their sights on polysaccharides. The two institutes will join forces to investigate how the arrangement of sugar molecules on DNA structures can be utilized to develop new antimicrobial agents. Planned to span a four-year period from May 2018, the “Glyco3Display” research project is being funded as part of the cooperation program between Fraunhofer and Max Planck.


Press information / 16.5.2018

Fraunhofer IZI steps up research to improve the treatment of infectious cardiovascular diseases

On 15 May 2018, international researchers and physicians gathered at Fraunhofer IZI to discuss new options in the treatment of infectious diseases affecting the cardiovascular system. The discussions focused in particular on adsorber systems, which wash out gram-negative bacteria using lipopolysaccharide (LPS) adsorbers in the blood.


Press information / 25.4.2018

Good Laboratory Practice (GLP) Test Facility at Fraunhofer IZI Recertified and Expanded

On 22 March 2018, the Saxon State Ministry of the Environment and Agriculture recertified the GLP test facility at Fraunhofer IZI. At the same time, part of the Molecular Drug Biochemistry and Therapy Development department at the IZI site in Halle (Saale) was issued with its first statement of GLP compliance as an independent test site. The certification process followed an inspection conducted at the respective GLP test sites by the competent authorities in the states of Saxony and Saxony-Anhalt from 8 - 10 November 2017.


Press information / 28.3.2018

Fraunhofer IZI receives grant from TaNeDS research program for new developments in the field of chronic inflammatory bowel disease

The Fraunhofer Institute for Cell Therapy and Immunology’s Rostock-based Extracorporeal Immunomodulation Department has been successful in its application for a grant in the field of pharmaceutical research offered by Japanese pharmaceutical company Daiichi Sankyo Company, Limited (Daiichi Sankyo). In line with the competition title "Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017", the team presented a project aimed at developing a new humanized mouse model which will improve research into inflammatory bowel disease (IBD). The project started in February 2018.


Fraunhofer IZI


Perlickstraße 1
04103 Leipzig

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000



Social Media